Sanofi New Results From Rilzabrutinib Phase 2 Study Show Potential To Be First Advanced Oral Treatment For Moderate-To-Severe Asthma; Data Shows Rilzabrutinib Led To Numerical Reduction In Loss Of Asthma Control Events, Improvement In Symptoms And Was...
Sanofi New Results From Rilzabrutinib Phase 2 Study Show Potential To Be First Advanced Oral Treatment For Moderate-To-Severe Asthma; Data Shows Rilzabrutinib Led To Numerical Reduction In Loss Of Asthma Control Events, Improvement In Symptoms And Was...
賽諾菲Rilzabrutinib 2期研究的新結果表明，有可能成爲首款治療中度至重度哮喘的高級口服療法；數據顯示，利扎布替尼導致哮喘失控事件的數量減少，症狀得到改善，並且...
Sanofi New Results From Rilzabrutinib Phase 2 Study Show Potential To Be First Advanced Oral Treatment For Moderate-To-Severe Asthma; Data Shows Rilzabrutinib Led To Numerical Reduction In Loss Of Asthma Control Events, Improvement In Symptoms And Was Well-Tolerated With No New Safety Signals Observed; Results Support The Further Development And Advancement Into A Phase 3 Program
賽諾菲Rilzabrutinib 2期研究的新結果表明，Rilzabrutinib有可能成爲首款中度至重度哮喘的高級口服治療藥物；數據顯示，利扎布替尼導致哮喘失控事件的數量減少，症狀得到改善，耐受性良好，未觀察到新的安全信號；結果支持3期計劃的進一步發展和推進
- Reuters
-路透社
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。